Anavar vs SARMs: How Oxandrolone Compares to Ostarine and RAD-140 for Results, Safety, and Evidence
The choice between Anavar and SARMs is one of the most common decisions facing anyone researching performance enhancement for the first time. SARMs are marketed as a safer, more targeted alternative to anabolic steroids: all the muscle-building benefits with fewer side effects. This marketing narrative is so widely repeated that many users treat it as established fact. It is not. The clinical reality of SARMs versus Anavar is that oxandrolone has five decades of controlled trial data, multiple FDA-approved clinical applications, and a well-characterised safety profile, while SARMs have a single completed Phase 1 trial (for RAD-140), a handful of Phase 2 and 3 trials (for ostarine, which failed to achieve FDA approval), and a growing body of case reports documenting liver injury, hormonal suppression, and contaminated products. This article compares Anavar vs SARMs across every dimension that matters: mechanism, evidence, liver safety, hormonal suppression, body composition outcomes, and legal status. At Hemi Pharma UK, we believe the comparison should be driven by data, not by marketing claims.
What Is the Fundamental Difference Between Anavar and SARMs at the Receptor Level?
Both oxandrolone and SARMs activate the androgen receptor. The difference is in selectivity and structural class. Oxandrolone is a steroidal compound: a modified dihydrotestosterone molecule with a C-2 lactone ring substitution. It activates androgen receptors in skeletal muscle, bone, and other tissues through the same nuclear receptor pathway as endogenous testosterone and DHT. Its selectivity for muscle over prostate is relative, not absolute, and is reflected in its anabolic-to-androgenic ratio of approximately 322:24.
SARMs (selective androgen receptor modulators) are non-steroidal compounds designed to bind the androgen receptor with tissue-specific selectivity. The theoretical promise is that they would activate the AR in muscle and bone (producing anabolic effects) while avoiding activation in prostate, skin, and liver (avoiding androgenic side effects). In preclinical models, this tissue selectivity was demonstrated: RAD-140 showed an anabolic-to-androgenic ratio of approximately 90:1 in rat assays.
The critical qualification is that tissue selectivity demonstrated in rat models has not been fully validated in humans. As the clinical data accumulated, it became clear that SARMs produce the same downstream consequences as AAS at the HPG axis (LH suppression, testosterone decline) and at the liver (cholestatic injury indistinguishable from AAS hepatotoxicity). The selectivity that was supposed to make SARMs fundamentally different from steroids has proven to be a matter of degree rather than kind.
How Does the Clinical Evidence for Anavar Compare to the Evidence for SARMs?
This is the most consequential difference in the entire Anavar vs SARMs comparison, and it is the one that SARM marketing materials never address.
Oxandrolone has been studied in dozens of randomised controlled trials across burn patients, HIV wasting, sarcopenia in elderly men, Turner syndrome in girls, post-surgical recovery, and constitutional delay of puberty. Body composition outcomes have been measured by DEXA and MRI. Protein synthesis rates have been quantified by stable isotope infusion. Strength changes have been tracked week by week. The drug received FDA approval in 1964 (as Anavar) and again in 1995 (as Oxandrin). Its safety profile is characterised across thousands of patients with decades of follow-up data.
Ostarine (MK-2866, enobosarm) is the most clinically studied SARM. It progressed to Phase 2 and Phase 3 trials for cancer cachexia (the POWER trials) but failed to achieve FDA approval. The Phase 2 data showed modest lean mass increases (approximately 1.0 to 1.5kg over 12 weeks at 3mg daily) in cancer patients, but the Phase 3 trials did not meet their primary endpoints for regulatory approval.
RAD-140 (testolone) has even less clinical data. Only one Phase 1 trial has been published, establishing basic pharmacokinetics and short-term tolerability. There are no Phase 2 or Phase 3 trials. No body composition outcomes have been measured in a controlled human study. Every claim about RAD-140’s anabolic effects in humans is extrapolated from preclinical animal data and anecdotal user reports.
The evidence asymmetry is stark. You are comparing a compound with 60 years of clinical trial data and multiple FDA approvals against compounds that have, at best, failed Phase 3 trials and, at worst, never progressed beyond Phase 1. When a user claims that SARMs are “proven to work,” they are almost certainly citing preclinical animal data or uncontrolled user experience, not human clinical trial outcomes.
Are SARMs Actually Safer Than Anavar for Your Liver?
This is the claim that has aged worst. When SARMs were first synthesised, researchers hoped their non-steroidal structure would avoid the hepatotoxicity associated with 17-alpha-alkylated oral AAS. The opposite has proven true: SARMs produce the same cholestatic liver injury pattern as traditional oral steroids, and in some cases, more severe injury than oxandrolone produces at standard doses.
A 2022 case report in the Ochsner Journal documented severe cholestatic drug-induced liver injury from RAD-140 in a previously healthy young man. His peak total bilirubin reached 38.5 mg/dL. Liver biopsy showed intracytoplasmic and canalicular cholestasis with minimal portal inflammation, a pathological pattern described as “indistinguishable from anabolic-androgenic steroid-induced hepatotoxicity.” The Drug-Induced Liver Injury Network causality score was 1 (probable) and the severity score was 3 (severe) (Gonzalez et al., 2022).
A 2024 case report in Cureus described another 29-year-old male who developed jaundice and elevated liver enzymes after three months of RAD-140 use, with hepatic steatosis and a hyperechoic lesion on ultrasound (Cureus, 2024). Similar cases have been reported for ostarine. The Gonzalez review noted that the bland cholestasis seen in both AAS and SARM liver injury “highly suggests” the same pathological mechanism is responsible.
Compare this to Anavar’s liver profile. Oxandrolone produces mild transaminase elevation (typically 1.5x to 2.5x ULN) in approximately 40% of users at bodybuilding doses, which is virtually always reversible and clinically benign. Severe cholestatic liver injury from oxandrolone at standard doses is exceedingly rare in the published literature. The paradox is that the compound marketed as “safer for your liver” (SARMs) has produced more cases of severe cholestatic injury per capita of users than the compound it was supposed to replace.
The important caveat is that SARM products purchased online are frequently contaminated, mislabelled, or adulterated. Studies analysing the contents of commercially available SARMs have found that a substantial proportion contain compounds other than or in addition to what is listed on the label. Some of the reported liver injuries may be attributable to contaminants rather than the SARM itself. This contamination risk is itself a safety concern: when you purchase a SARM from an unregulated source, you do not know what you are taking. Every batch of Hemi Pharma Oxandrolone is independently tested by Janoshik Analytical, confirming identity and purity. No SARM vendor offers comparable third-party verification.
Do SARMs Suppress Testosterone Less Than Anavar?
This is the second major SARM marketing claim, and it is partially true but clinically misleading. SARMs do suppress the HPG axis, but the degree of suppression varies by compound and dose. Ostarine at low doses (1 to 3mg daily, the clinical trial range) produces modest testosterone suppression that may not require PCT. RAD-140 at the doses used by bodybuilders (10 to 30mg daily, far above the Phase 1 trial doses) produces significant testosterone suppression that is functionally indistinguishable from AAS-induced suppression.
Anavar at bodybuilding doses (30mg to 60mg daily) produces comprehensive HPTA suppression, as documented in our Anavar only cycle article. The comparison is therefore dose-dependent. At clinical trial doses (where SARMs were studied at 1 to 3mg), SARMs produce less suppression. At bodybuilding doses (where both compounds are used in practice), the difference narrows substantially. RAD-140 users at 20mg daily routinely report hypogonadal symptoms and require PCT, just as Anavar users do.
The practical question is not whether SARMs suppress testosterone (they do), but whether the degree of suppression at effective bodybuilding doses is meaningfully different from Anavar. For ostarine at 10 to 25mg daily (the typical bodybuilding range), suppression is moderate and recovery is generally faster. For RAD-140 at 10 to 30mg daily, suppression is significant and PCT is recommended by the user community. For Anavar at 30 to 60mg daily, suppression is comprehensive and PCT is clinically indicated. The spectrum is a continuum, not a binary distinction.
Which Produces Better Body Composition Results: Anavar or SARMs?
Anavar, by a significant margin. The controlled trial data on oxandrolone shows lean body mass gains of 2 to 3kg, fat mass reductions of 1.5 to 2kg, and visceral fat reductions of 20cm² by MRI over 8 to 12 weeks at 20mg daily in clinical populations. At bodybuilding doses (40 to 60mg daily) in trained individuals with optimised nutrition, the effects are proportionally greater.
Ostarine’s Phase 2 data showed lean mass gains of approximately 1.0 to 1.5kg at 3mg daily over 12 weeks in cancer cachexia patients. At bodybuilding doses (25mg daily), anecdotal reports suggest modest lean mass gains (1 to 2kg) with some fat loss over 8 to 12 weeks. RAD-140 has no controlled human body composition data at all. Anecdotal reports from bodybuilding users describe effects comparable to a low-dose Anavar cycle (15 to 20mg daily), but without the clinical evidence to substantiate the comparison.
The body composition comparison favours Anavar on three levels: stronger absolute effects, better clinical evidence quality, and proven durability (the Schroeder study showed 83% fat loss retention 12 weeks post-cessation). SARMs have no comparable durability data because no controlled post-cessation follow-up studies have been published.
Is the Legal Status of SARMs an Advantage Over Anavar in the UK?
In the UK, anabolic steroids including oxandrolone are Class C controlled substances under the Misuse of Drugs Act 1971. Possession for personal use is legal. Supply, distribution, and importation with intent to supply are criminal offences. SARMs are not classified as controlled substances under the Misuse of Drugs Act. They are, however, prohibited for sale as supplements or for human consumption, and they are banned by WADA under category S1.2 (other anabolic agents).
The practical legal difference is minimal for personal use. You can legally possess Anavar for personal use in the UK. You can legally purchase SARMs as “research chemicals” in the UK. Neither can be legally sold as a supplement or medication without appropriate licensing. The legal distinction does not translate into a meaningful safety or access advantage for SARMs.
The more significant practical difference is product quality assurance. Pharmaceutical-grade oxandrolone from verified manufacturers undergoes analytical testing that confirms identity, purity, and dosage. SARMs are sold as research chemicals with no pharmaceutical manufacturing standards, no consistent quality control, and documented contamination rates that would be unacceptable in any regulated industry.
Frequently Asked Questions
Should I try SARMs before Anavar because they are milder?
The premise is flawed. SARMs are not categorically milder. They produce testosterone suppression, liver injury (including severe cholestatic hepatotoxicity documented in multiple case reports), and lipid changes. They are less well-studied, less well-characterised, and more likely to be contaminated than pharmaceutical-grade oxandrolone. If “milder” means “less clinical evidence of what happens when you take it,” then SARMs qualify. If it means “less likely to cause harm,” the available data does not support that conclusion for Anavar vs SARMs at bodybuilding doses.
Can I stack Anavar with a SARM?
Stacking Anavar with a SARM compounds the HPTA suppression from both compounds without evidence that the combination produces additive anabolic effects. Both activate the androgen receptor; adding a second AR agonist on top of a saturating Anavar dose produces diminishing returns while doubling the suppressive and hepatic burden. If you want to add a second compound to Anavar, a testosterone base is pharmacologically rational. A SARM is not.
Are SARMs better for hair than Anavar?
Not necessarily. Both SARMs and Anavar activate the androgen receptor, and androgenic activity at the hair follicle is an AR-mediated effect. The degree of hair loss risk depends on the compound’s androgenic potency at the follicle and the user’s genetic susceptibility. Anavar has a very low androgenic rating (24). RAD-140’s hair loss potential is poorly characterised because no human hair follicle studies have been conducted. Anecdotal reports suggest RAD-140 produces comparable or greater shedding than Anavar in susceptible individuals, but controlled data does not exist for either compound in this specific comparison.
Do SARMs require PCT like Anavar does?
At bodybuilding doses, yes. RAD-140 at 10 to 30mg daily produces significant testosterone suppression that the user community universally recommends PCT for. Ostarine at 10 to 25mg daily produces moderate suppression; some users recover without PCT, while others require it. The distinction is dose-dependent. At clinical trial doses (1 to 3mg), SARMs produce minimal suppression. At bodybuilding doses, the suppression is substantial enough that PCT with tamoxifen or clomiphene is widely practised.
Why do so many people choose SARMs over Anavar if Anavar is better supported by evidence?
Marketing, perceived legality, needle avoidance, and the appeal of “novel” compounds. SARMs are marketed aggressively online as a modern, scientific alternative to “old” steroids. The non-steroidal label creates the impression of a fundamentally different safety profile. The oral-only administration avoids the psychological barrier of injection (though Anavar is also oral). And the research chemical loophole allows open online sale without the stigma of purchasing a controlled substance. None of these factors change the pharmacological comparison. Anavar has 60 years of clinical evidence. SARMs have marketing.